The Cell and Gene Therapy Catapult (CGT Catapult) has outlined the latest guidance on the development and marketing of ATMPs in the UK. The guidance covers legislative changes as a result of the United Kingdom leaving the European Union, including topics such as clinical trials, ATMP classifications, UK Marketing Authorisations, UK Paediatric Investigation Plans, orphan drug designation, MHRA submission platform and advice meetings.
The guide is available as a PDF to download or view online.
